Congress Materials – American Academy of Dermatology (AAD 2025)
2025 American Academy of Dermatology | Mar 7-11 | Orlando, FL
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Icotrokinra, a Targeted Oral Peptide That Selectively Blocks the Interleukin-23–Receptor, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, Randomized, Double-blind, Placebo-Controlled ICONIC-LEAD Trial
Melinda Gooderham, Edward Lain, Robert Bissonnette, Yu-Huei Huang, Charles Lynde, Matthias Hoffmann, Eingun James Song, Jessica H. Rubens, Amy M. DeLozier, Ming-Chun Hsu, Richard B. Warren
Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis in Pediatric Patients: Results of a Phase 3, Randomized, Placebo-Controlled Study
Vimal H. Prajapati, Marieke M.B. Seyger, Dagmar Wilsmann-Theis, Erzsebet Szakos, Andrzej Kaszuba, Meg Jett, Bart van Hartingsveldt, Gigi Jiang, Shu Li, Cynthia DeKlotz, Amy S. Paller
Pharmacokinetics of guselkumab in super responders and long-term psoriasis disease control: Insights from the Phase 3b GUIDE trial
K. Eyerich, K. Asadullah, A. Pinter, P. Weisenseel, C. Paul, F. Kreimendahl, K. Henry, J. Wilke, N. Krüger, N. Spindler, K. Schäkel
SPECTREM: Guselkumab Demonstrates Consistent Significant Clearance Across the Full Range of Low Body Surface Area, Moderate Psoriasis With Special Sites Involvement
L Stein Gold, B Strober, AW Armstrong, T Alkousakis, KA Papp, R Langley, O Choi, D Chan, J Jeyarajah, V Groysman, MG Lebwohl
SPECTREM: Guselkumab Demonstrates Significant Clearance Across the Most Commonly Presenting Special Sites in Participants with Low BSA Moderate Psoriasis
AB Gottlieb, J Krueger, KB Gordon, R Bissonnette, T Alkousakis, O Salgado, O Choi, D Chan, J Jeyarajah, J Garcia-Zuazaga, JF Merola
THE VISIBLE STUDY: BURDEN OF COMORBIDITIES IN PARTICIPANTS WITH MODERATE-TO-SEVERE PSORIASIS ACROSS ALL SKIN TONES
L. Stein Gold, G. Han, M. Shahriari, O. Choi, T. Alkousakis, T. Ma, D. Chan, L. Green, A. Farberg, S.G. Kwatra, A. Alexis
VISIBLE COHORT A: GUSELKUMAB DEMONSTRATED SKIN CLEARANCE AND IMPROVED HEALTH-RELATED QUALITY OF LIFE THROUGH WEEK 48 IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS ACROSS ALL SKIN TONES
A. Alexis, A.O. Rodriguez, G. Yadav, S.K. Tyring, O. Choi, T. Alkousakis, D. Chan, T. Ma, M. Sauder, J. Alonso-Llamazares, S.R. Desai
VISIBLE COHORT B: GUSELKUMAB DEMONSTRATED SCALP CLEARANCE AND IMPROVED HEALTH-RELATED QUALITY OF LIFE THROUGH WEEK 48 IN PARTICIPANTS WITH MODERATE-TO-SEVERE SCALP PSORIASIS ACROSS ALL SKIN TONES
A. McMichael, T. Bhutani, S. Smith, T. Alkousakis, O. Choi, D. Chan, T. Ma, R. Radusky, J. Yeung, G. Han, S.C. Taylor
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.